erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
Endometrial cancer is the most common female genital tract malignancy in the United States. Type I endometrial cancer is usually diagnosed at an early stage, and has a good prognosis. Type II is very aggressive, and is responsible for most uterine cancer relapses and deaths. Uterine serous adenocarc...
Saved in:
Main Authors: | Karim S. ElSahwi (Author), Alessandro D. Santin (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2011-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
by: Sho Ueno, et al.
Published: (2020) -
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017) -
Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy
by: Antonio Villalobo, et al.
Published: (2013) -
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
by: Juliana Bentes Hughes, et al.
Published: (2012) -
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
by: Blair McNamara, et al.
Published: (2023)